期刊文献+

重组人血小板生成素可能通过调节免疫负调控因子水平治疗免疫性血小板减少性紫癜 被引量:8

The Effects on Immune System in Patients with Immune Thrombocytopenic Treated by Recombinant Human Thrombopoietin
下载PDF
导出
摘要 目的观察使用重组人血小板生成素(rh TPO,特比澳)前后免疫性血小板减少性紫癜(ITP)患者血浆IL-10,CTLA-4,TGF-β1变化情况,并与肾上腺皮质激素治疗前后ITP患者以及正常人血浆IL-10,CTLA-4,TGF-β1含量的比较。方法采用酶联免疫吸附试验(ELISA)测定21例ITP患者(其中11例使用rh TPO治疗,10例使用肾上腺皮质激素治疗)治疗前、后及15名正常对照者血浆IL-10,CTLA-4,TGF-β1水平,并对检测结果进行分析。结果 ITP患者血浆中IL-10、CTLA-4、TGF-β1水平明显低于正常人;经rh TPO或肾上腺皮质激素治疗后IL-10,CTLA-4,TGF-β1水平均有明显升高,并恢复至正常人水平;rh TPO及肾上腺皮质激素升高ITP患者血浆中IL-10,CTLA-4,TGF-β1水平的程度无差别。结论 ITP患者IL-10,CTLA-4,TGF-β1水平低于正常人,经治疗后水平可恢复正常;单用rh TPO后三种细胞因子水平显著升高,提示rh TPO可能有免疫调节的作用。 Objective To investigate the changes of the levels of plasma contents of 3 cytokines(IL-10,CTLA-4,TGF-β1)of immune thrombocytopenic purpura (ITP)patients treated by recombinant human thrombopoietin (rhTPO) or steroid.Methods We use Enzyme-linked immunosorbent assay (ELISA) to measured the levels of 3 cytokines of 21 ITP patients(11 patients was treated by rhTPO,10 patients was treated by steroid) before and after the treatment,and 15 healthy people were measured as control.Results The levels for ITP patient' s plasma contents of both 3 cytokines were significantly lower than normal ; after the treatment of rhTPO or steroid,levels were significantly higher,and recovery to normal levels.Conclusion The levels of plasma contents of 3 cytokines (IL-10,CTLA-4,TGF-β1) of ITP patients were lower than normal,and return to normal levels after treatment; the use of rhTPO can significantly increased the levels of 3 cytokines,suggesting that rhTPO may modulate immune system.
出处 《血栓与止血学》 2014年第6期315-318,共4页 Chinese Journal of Thrombosis and Hemostasis
关键词 免疫性血小板减少性紫癜 重组人血小板生成素 白细胞介素10 细胞毒T淋巴细胞相关抗原4 转化生长因子Β1 Immune thrombocytopenic purpura Recombinant human thrombopoietin Interleukin-10 Cytotoxic T lymphocyte-associated antigen-4 Transforming growth factor-β1
  • 相关文献

参考文献9

  • 1赵永强,王庆余,翟明,徐健,陈协群,刘文励,张梅,宋善俊,王健民,孟凡义,单渊东.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的多中心临床试验[J].中华内科杂志,2004,43(8):608-610. 被引量:102
  • 2BAO W, BUSSEL JB, HECK S, et al. Improved regulatory T- cell activity in patients with chronic immune thrombocytope- nia treated with thrombopoietic agents[ J ]. Blood ,2010,116 ( 22 ) :4639-4645.
  • 3张之南、沈悌,血液病诊断和疗效标准第三版[M],北京:科学出版社,2008:172-176.
  • 4无,侯明.成人原发免疫性血小板减少症诊断与治疗中国专家共识(2012年版)[J].中华血液学杂志,2012,33(11):975-977. 被引量:191
  • 5FUJITA S, NAKANISHI T, OSHIMURA H, et al. TGF[3 (1) and sCTLA-4 levels are increased in ehrombopag-ex- posed patients with ITP[J]. Thromb Res,2012,130, (9) : 415-419.
  • 6KUBO M, MOTOMURA Y. Transcriptional regulation of the anti-inflammatory cytokine IL-10 in acquired immune cells. [ J] Front Immuno1,2012,3 ( 275 ) : 1-9.
  • 7OAKS MK, HALLETr KM. A soluble form of CTLA-4 in pa- tients with autoimmune thyroid disease [ J ]. lmmunol,2000, 164:5015-5018.
  • 8WAN YY, FLAWELL RA. ' Yin-Yang' functions of transfor- ming growth factor-beta and regulatory cells in immune reg- ulation. [ J] Immunol Rev,2007,220 : 199-213.
  • 9FOURNIE, G. J, CAUTAIN B, XYSTRAKIS E, et al. Cellular and genetic factors involved in the difference between Brown Norway and Lewis rats to develop respectively type-2 and type- 1 immune-mediated diseases[ J]. Immunol Rev,2001, 184 : 145-160.

二级参考文献8

共引文献282

同被引文献89

引证文献8

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部